secwatch.observer — SEC 8-K summary
======================================

Issuer:     COLLEGIUM PHARMACEUTICAL, INC (COLL)
CIK:        0001267565
Form:       8-K
Filed at:   2025-05-08T23:59:59+00:00
Accession:  0001558370-25-006957
Event type: earnings
Sentiment:  positive
Materiality: 0.75
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Collegium Q1 revenue up 23% to $177.8M; guides FY25 $735-750M; authorizes $25M ASR
--------------------------------------------------------------------------------

- Q1 net revenue $177.8M (+23% YoY); Jornay PM $28.5M (+24% Rx growth); pain portfolio $149.2M (+3%).
- GAAP net income $2.4M ($0.07 diluted EPS); non-GAAP adj. net income $57.4M ($1.49 adj. EPS).
- Adjusted EBITDA $95.2M (+3% YoY); cash & securities $197.8M, up from $162.8M at Dec 31, 2024.
- Board authorized $25M accelerated share repurchase; paid down $16.1M in debt during Q1.
- Expanded Jornay PM sales force to ~180 reps; new Chairman, board members, and execs appointed.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1267565/000155837025006957/0001558370-25-006957-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1267565/000155837025006957/coll-20250508x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-25-006957

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer